Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH001 in moderate-to-severe atopic dermatitis
NCT07054736Phase 2Not yet recruiting
- Sponsor
- Kanova
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XKH001 Placebo Injection in atopic dermatitis (AD) (4 arms), sponsored by Kanova. Primary endpoints: Primary Objective 1 at Week 16 and Primary Objective 2 at Week 16. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
XKH001 Placebo Injection
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07054736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054736.